Shree Ganesh Biotech (India) Ltd
Shree Ganesh Biotech (India) Ltd (SHREEGANES) last reported results for the quarter ended Jun 2026, with sales of ₹1.43 crore and net profit of ₹-0.57 crore. The stock last traded at ₹0.48, a market capitalisation of ₹19.1 crore. Over the past 52 weeks the stock has ranged between ₹0.46 and ₹0.78. Figures are as of 6 Oct 2026 and are not real time.
Shree Ganesh Biotech (India) Ltd share price and key metrics
- Current price
- ₹0.48
- Market cap
- ₹19.1 cr
- Book value
- ₹1.6
- ROE
- 0.96%
- ROCE
- 1.31%
- Dividend yield
- 0.00%
- 52w high / low
- 0.78/0.46
Metrics as of 6 Oct 2026. Not real time.
Track Shree Ganesh Biotech (India) Ltd
Cruxal reads every Shree Ganesh Biotech (India) Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Shree Ganesh Biotech (India) Ltd growth and returns
- 10 Years
- 9%
- 5 Years
- -22%
- 3 Years
- -57%
- TTM
- -76%
- 10 Years
- 1%
- 5 Years
- 3%
- 3 Years
- -33%
- TTM
- -183%
- 10 Years
- %
- 5 Years
- -42%
- 3 Years
- -17%
- 1 Year
- -38%
- 10 Years
- 3%
- 5 Years
- 2%
- 3 Years
- 1%
- Last Year
- 1%
Shree Ganesh Biotech (India) Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹1.43 cr, up 3.6% from ₹1.38 cr a year earlier. Net profit swung to a loss of ₹0.57 cr.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1.98 | 14.41 | 3.01 | 1.38 | 0.77 | 0.7 | 2.12 | 1.43 |
| Expenses | 1.96 | 13.94 | 4.43 | 1.47 | 1.17 | 0.75 | 2.55 | 2.32 |
| Operating profit | 0.02 | 0.47 | -1.42 | -0.09 | -0.4 | -0.05 | -0.43 | -0.89 |
| OPM % | 1.01% | 3.26% | -47.18% | -6.52% | -51.95% | -7.14% | -20.28% | -62.24% |
| Other income | 0.3 | 0.3 | 0.47 | 0.42 | 0.41 | 0.37 | 0.28 | 0.32 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0.32 | 0.77 | -0.95 | 0.33 | 0.01 | 0.32 | -0.15 | -0.57 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net profit | 0.32 | 0.77 | -0.95 | 0.33 | 0.01 | 0.32 | -0.15 | -0.57 |
| EPS (₹) | 0.01 | 0.02 | -0.02 | 0.01 | 0.00 | 0.01 | -0.00 | -0.01 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Shree Ganesh Biotech (India) Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 8.54 | 7.86 | 5.87 | 2.47 | 17.21 | 72.64 | 62.45 | 20.28 | 22.96 | 4.97 | 5.02 |
| Operating profit | 3.76 | 3.5 | 1.79 | 0.24 | 0.71 | 3.45 | 2.15 | -0.2 | -0.96 | -0.64 | -1.77 |
| OPM % | 44.03% | 44.53% | 30.49% | 9.72% | 4.13% | 4.75% | 3.44% | -0.99% | -4.18% | -12.88% | -35.26% |
| Net profit | 3.73 | 3.5 | 1.79 | 0.24 | 0.32 | 2.53 | 2.04 | 0.62 | 0.28 | 0.38 | -0.39 |
| EPS (₹) | 1.01 | 0.95 | 0.04 | 0.01 | 0.01 | 0.06 | 0.05 | 0.02 | 0.01 | 0.01 | 0.00 |
TTM is the trailing twelve months to the most recent quarter.
Shree Ganesh Biotech (India) Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 1.83 | 1.83 | 19.93 | 19.93 | 19.93 | 19.93 | 39.86 | 39.86 | 39.86 | 39.86 |
| Reserves | 17.54 | 21.04 | 37.31 | 37.54 | 37.86 | 40.39 | 22.49 | 23.12 | 23.39 | 23.77 |
| Borrowings | 0.06 | 0.19 | 0.19 | 0.19 | 0.19 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other liabilities | 0.01 | 3.30 | 6.66 | 7.06 | 16.64 | 33.24 | 17.18 | 10.64 | 0.24 | 0.17 |
| Total liabilities | 19.44 | 26.36 | 64.09 | 64.72 | 74.62 | 93.56 | 79.53 | 73.62 | 63.49 | 63.80 |
| Fixed assets | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 3.06 | 3.22 | 0.00 | 0.00 | 9.15 | 9.15 |
| Other assets | 19.44 | 26.36 | 64.08 | 64.72 | 71.56 | 90.34 | 79.53 | 73.62 | 54.34 | 54.65 |
| Total assets | 19.44 | 26.36 | 64.09 | 64.72 | 74.62 | 93.56 | 79.53 | 73.62 | 63.49 | 63.80 |
As reported by the company. Total assets equal total liabilities by construction.
Shree Ganesh Biotech (India) Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -12.94 | 2.23 | -0.50 | -1.01 | 2.36 | 3.57 | 10.54 | 10.16 | -10.21 | -8.20 |
| Cash from investing | 2.53 | -2.36 | -32.07 | 0.99 | -2.36 | -3.37 | -10.09 | -10.21 | 9.80 | 8.19 |
| Cash from financing | 10.42 | 0.13 | 32.58 | 0.00 | 0.00 | -0.19 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net cash flow | 0.02 | 0.00 | 0.01 | -0.02 | 0.01 | 0.01 | 0.44 | -0.05 | -0.41 | 0.00 |
| Free cash flow | -10.62 | 2.23 | -0.51 | -1.01 | 2.36 | 3.57 | 10.54 | 10.16 | -10.21 | -8.20 |
| CFO / operating profit | -344% | 64% | -28% | -421% | 348% | 132% | 522% | -5,080% | 1,052% | 1,259% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Shree Ganesh Biotech (India) Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 30.45% | 16.47% | 4.45% | 0.42% | 1.23% | 5.92% | 4.42% | 1.37% | 0.76% | 1.31% |
| Debtor days | 384.23 | 627.84 | 1,191.38 | 3,072.21 | 601.05 | 220.54 | 112.98 | 59.39 | 0.00 | 0.00 |
| Inventory days | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 46.59 | 846.14 |
| Days payable | — | — | — | — | — | — | — | — | 0.00 | 0.00 |
| Cash conversion cycle | 384.23 | 627.84 | 1,191.38 | 3,072.21 | 601.05 | 220.54 | 112.98 | 59.39 | 46.59 | 846.14 |
| Working capital days | 383.81 | 475.99 | 779.12 | 2,036.32 | 249.20 | 53.71 | 12.80 | -132.11 | 50.08 | 860.72 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Shree Ganesh Biotech (India) Ltd shareholding pattern
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| FIIs | 1.42% | 1.42% | 1.42% | 1.42% | 1.42% | 1.42% | 1.42% | 1.42% |
| Public | 98.57% | 98.58% | 98.58% | 98.58% | 98.58% | 98.58% | 98.59% | 98.59% |
| No. of shareholders | 1,85,335 | 1,92,040 | 1,95,435 | 1,92,235 | 1,89,375 | 1,86,148 | 1,83,658 | 1,81,722 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Shree Ganesh Biotech (India) Ltd corporate filings
- PFACompany Updatelow impact
- Shree Ganesh Bio-Tech (India) Limited Announces Voting Results of 16th Annual General MeetingAGM/EGMlow impact
Cruxal's analysis: Shree Ganesh Bio-Tech (India) Limited has disclosed the voting results for its 16th…
Read the full analysis - Shree Ganesh Bio-Tech (India) Limited concludes 16th Annual General MeetingAGM/EGMlow impact
Cruxal's analysis: Shree Ganesh Bio-Tech (India) Limited has formally concluded its 16th Annual General…
Read the full analysis - PFAInsider Trading / SASTlow impact
- Shree Ganesh Biotech (India) Ltd submits Annual Report for FY 2025-26 and schedules 16th AGMOtherslow impact
Cruxal's analysis: Shree Ganesh Biotech (India) Ltd has filed its Annual Report for the financial year…
Read the full analysis - Shree Ganesh Biotech (India) Ltd announces book closure for AGMCorp. Actionlow impact
Cruxal's analysis: Shree Ganesh Biotech (India) Ltd has issued an intimation regarding the closure of its…
Read the full analysis - Shree Ganesh Bio-Tech (India) Limited Announces 16th Annual General Meeting for September 28, 2026AGM/EGMlow impact
Cruxal's analysis: Shree Ganesh Bio-Tech (India) Limited has issued a formal notice for its 16th Annual…
Read the full analysis - Shree Ganesh Biotech (India) Ltd updates corporate websiteCompany Updatelow impact
Cruxal's analysis: Shree Ganesh Biotech (India) Ltd has issued a routine notification regarding an update to…
Read the full analysis - Shree Ganesh Biotech files routine disclosure under SEBI Regulation 32(1)Company Updatelow impact
Cruxal's analysis: Shree Ganesh Biotech (India) Ltd submitted a disclosure under Regulation 32(1) of SEBI…
Read the full analysis - Shree Ganesh Bio-Tech reports significant Q1 FY27 net loss of INR 57.32 lakhs, reversing prior year's profit amid weak revenue growth and widening quarterly losses.Board Meetinghigh impact
Cruxal's analysis: Shree Ganesh Bio-Tech (India) Limited has announced its unaudited financial results for…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.